New Scientist on MSN
Treating cancer before 3pm could help patients live longer
The most robust evidence to date shows that people with a type of lung cancer lived longer if they received immunotherapy before 3pm ...
Recommendation based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% ...
February 2026 Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers Recommendation based on MATTERHORN Phase III trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results